Carcinoma, Hepatocellular

Showing NaN - NaN of 18

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)

Recruiting
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +62 more
Feb 1, 2023

Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +138 more
Aug 22, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab, Sorafenib)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Phoenix, Arizona
  • +118 more
Jun 14, 2022

Carcinoma, Hepatocellular Trial in Hong Kong (embolization)

Recruiting
  • Carcinoma, Hepatocellular
  • embolization
  • Hong Kong, Hong Kong
    Department of Imaging and Interventional Radiology, Prince of Wa
Mar 10, 2022

Carcinoma, Hepatocellular Trial in Hong Kong (Ablative chemoembolization (ACE))

Recruiting
  • Carcinoma, Hepatocellular
  • Ablative chemoembolization (ACE)
  • Hong Kong, Hong Kong
    Department of Imaging and Interventional Radiology, Prince of Wa
Mar 10, 2022

Carcinoma, Hepatocellular Trial in Worldwide (biological, drug, other)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • pembrolizumab
  • +2 more
  • Hefei, Anhui, China
  • +40 more
Mar 3, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766), Sorafenib (BAY43-9006))

Completed
  • Carcinoma, Hepatocellular
  • Refametinib (BAY86-9766)
  • Sorafenib (BAY43-9006)
  • Louisville, Kentucky
  • +78 more
Apr 6, 2021

Carcinoma, Hepatocellular, Secondary Trial in Hong Kong (Sorafenib, Capecitabine, Oxaliplatin)

Completed
  • Carcinoma, Hepatocellular
  • Secondary
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Apr 9, 2020

Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo)

Completed
  • Carcinoma, Hepatocellular
  • Sorafenib (Nexavar, BAY43-9006)
  • +2 more
  • San Francisco, California
  • +126 more
May 16, 2019

Carcinoma, Hepatocellular Trial in Worldwide (Nexavar (Sorafenib, BAY43-9006), Placebo)

Completed
  • Carcinoma, Hepatocellular
  • Nexavar (Sorafenib, BAY43-9006)
  • Placebo
  • Birmingham, Alabama
  • +198 more
Jul 11, 2018

Carcinoma, Hepatocellular Trial in San Francisco, Hong Kong, Taipei (pazopanib)

Completed
  • Carcinoma, Hepatocellular
  • San Francisco, California
  • +2 more
Nov 13, 2017

Carcinoma, Hepatocellular Trial in Hong Kong, Taiwan, Thailand (Foretinib)

Completed
  • Carcinoma, Hepatocellular
  • Hong Kong, Hong Kong
  • +6 more
Jul 14, 2017

Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin, Doxorubicin/Placebo)

Completed
  • Carcinoma, Hepatocellular
  • Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
  • Doxorubicin/Placebo
  • Birmingham, Alabama
  • +27 more
Oct 24, 2014

Carcinoma, Hepatocellular Trial in Worldwide (BAY86-9766 MEK Inhibitor + Sorafenib)

Completed
  • Carcinoma, Hepatocellular
  • BAY86-9766 MEK Inhibitor + Sorafenib
  • Shatin, New Territories, Hong Kong
  • +14 more
Sep 5, 2013

Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular Trial in Worldwide

Terminated
  • Hepatocellular Carcinoma Non-resectable
  • +12 more
  • Beverly Hills, California
  • +162 more
Sep 7, 2012

Carcinoma, Hepatocellular Trial in Hong Kong (Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Pegylated

Unknown status
  • Carcinoma, Hepatocellular
  • Transcatheter Arterial Chemoembolization (TACE)
  • Transcatheter Arterial Pegylated Interferon Embolization (TAIE)
  • Hong Kong, China
    Queen Mary Hospital
Jul 6, 2010

Carcinoma, Hepatocellular, Liver Tumors Trial in Hong Kong, Singapore, Taiwan (Photodynamic therapy, Talaporfin Sodium)

Completed
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Photodynamic therapy
  • Talaporfin Sodium
  • Hong Kong, Hong Kong
  • +8 more
Dec 5, 2007